PCMA Research Hub
The Unintended Consequences of the DOL PBM Transparency Rule: An Ode to the Little Guy (and Gal)
By Amanda Frost, PhD Vice President, Research, PCMA The law of unintended consequences, when an action produces unexpected effects outside of its goal. The ripple effect, a single small action causing a chain of larger reactions. The butterfly effect, where small changes early on lead to big unpredictable effects down the road. What do all […]
Want to Understand the Prescription Drug Supply Chain? Start at the Wholesalers
By Amanda Frost, PhD Vice President, Research, PCMA Last year, the U.S. spent $1.363 trillion on prescription drugs, and every year we spend more. We all want this money to be invested in healthier lives for Americans. But do we know if we’re getting our money’s worth? Policymakers have recently been asking this question and […]
How the Future of GLP-1 Affordability Depends on Competition
By Amanda Frost, PhD Vice President, Research, PCMA There is no shortage of opinions these days about GLP-1 prescription drugs: touting benefits for patients; concerns about sky-rocketing drug costs for employers and governments; praise for manufacturers lowering the list prices; and, of course, one brand drug company suing another over their “misleading” television advertisements. And […]
From Flashy Ads to Expensive Drugs: 5 Things You Need to Know About Misleading Drug Advertisements
By Amanda Frost, PhD Vice President, Research, PCMA I don’t watch much television these days, but when I do, I can be assured of one thing: I will be inundated with commercials advertising prescription drugs. According to one study, there were 1.35 million drug commercials aired in 2025. And these commercials have real impact. Research shows that consumers who watch these ads […]
